Back to Archived Journals » Current Biomarker Findings » Volume 3

Microaneurysm turnover in the macula is a biomarker for development of clinically significant macular edema in type 2 diabetes

Authors Ribeiro L, Nunes S, Cunha-Vaz J

Received 16 November 2012

Accepted for publication 13 December 2012

Published 17 January 2013 Volume 2013:3 Pages 11—15


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Luisa Ribeiro, Sandrina Nunes, José Cunha-Vaz

Association for Innovation and Biomedical Research on Light and Image and Faculty of Medicine, University of Coimbra, Coimbra, Portugal

Abstract: The evolution and progression of diabetic retinopathy varies between individuals and does not necessarily progress to vision loss in every patient. However, it is difficult in clinical practice to predict the clinical course and to identify which eyes will develop vision-threatening complications, ie, clinically significant macular edema or proliferative retinopathy. There is a clear need to identify biomarkers of disease progression. Microaneurysm turnover computed automatically in digital color fundus photography images using the RetmarkerDR is a good biomarker for worsening of retinopathy and development of clinically significant macular edema. For long-term prediction (ten years), a microaneurysm formation rate higher than two per year predicts development of clinically significant macular edema. For short-term prediction (2 years), a microaneurysm turnover rate lower than nine indicates that development of clinically significant macular edema is highly unlikely.

Keywords: biomarker, diabetes type 2, diabetic retinopathy, microaneurysms, retina

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]